Differential mechanisms underlying methotrexate-induced cell death and epithelial-mesenchymal transition in A549 cells |
Ojima, Takamichi
(Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University)
Kawami, Masashi (Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University) Yumoto, Ryoko (Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University) Takano, Mikihisa (Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University) |
1 | Tang L (2019) Investigating heterogeneity in HeLa cells. Nat Methods 16:281. https://doi.org/10.1038/s41592-019-0375-1 DOI |
2 | Ben-David U, Siranosian B, Ha G et al (2018) Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560:325-330. https://doi.org/10.1038/s41586-018-0409-3 DOI |
3 | Yang Y, Pan X, Lei W, Wang J, Song J (2006) Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 25:7235-7244. https://doi.org/10.1038/sj.onc.1209712 DOI |
4 | El-Deiry WS (2016) p21 (WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res 76:5189-5191. https://doi.org/10.1158/0008-5472.CAN-16-2055 DOI |
5 | Kawami M, Harabayashi R, Harada R, Yamagami Y, Yumoto R, Takano M (2018) Folic acid prevents methotrexate-induced epithelial-mesenchymal transition via suppression of secreted factors from the human alveolar epithelial cell line A549. Biochem Biophys Res Commun 497:457-463. https://doi.org/10.1016/j.bbrc.2018.02.111 DOI |
6 | Fekry B, Esmaeilniakooshkghazi A, Krupenko SA, Krupenko NI (2016) Ceramide synthase 6 is a novel target of methotrexate mediating its antiproliferative effect in a p53-dependent manner. PLoS ONE 11:e0146618. https://doi.org/10.1371/journal.pone.0146618 DOI |
7 | Li XL, Hara T, Choi Y et al (2014) A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol Cell Biol 34:533-550. https://doi.org/10.1128/mcb.01043-13 DOI |
8 | Rahmanian N, Hosseinimehr SJ, Khalaj A (2016) The paradox role of caspase cascade in ionizing radiation therapy. J Biomed Sci 23:88. https://doi.org/10.1186/s12929-016-0306-8 DOI |
9 | Hattangadi DK, DeMasters GA, Walker TD et al (2004) Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem Pharmacol 68:1699-1708. https://doi.org/10.1016/j.bcp.2004.06.033 DOI |
10 | Fischer KR, Durrans A, Lee S et al (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472-476. https://doi.org/10.1038/nature15748 DOI |
11 | Brosh R, Assia-Alroy Y, Molchadsky A et al (2013) p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ 20:312-320. https://doi.org/10.1038/cdd.2012.125 DOI |
12 | Kawami M, Harada R, Ojima T, Yamagami Y, Yumoto R, Takano M (2019) Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology 424:152231. https://doi.org/10.1016/j.tox.2019.06.002 DOI |
13 | Chang CJ, Chao CH, Xia W et al (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13:317-323. https://doi.org/10.1038/ncb2173 DOI |
14 | Abbas T, Dutta A (2009) P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400-414. https://doi.org/10.1038/nrc2657 DOI |
15 | Grassi ML, Palma Cde S, Thome CH, Lanfredi GP, Poersch A, Faca VM (2017) Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control. J Proteomics 151:2-11. https://doi.org/10.1016/j.jprot.2016.06.009 DOI |
16 | Zhang Y, Yan W, Jung YS, Chen X (2016) PUMA cooperates with p21 to regulate mammary epithelial morphogenesis and epithelial-to-mesenchymal transition. PLoS ONE 8:e66464. https://doi.org/10.1371/journal.pone.0066464 DOI |
17 | Termen S, Tan EJ, Heldin CH, Moustakas A (2013) p53 regulates epithelial-mesenchymal transition induced by transforming growth factor β. J Cell Physiol 228:801-813. https://doi.org/10.1002/jcp.24229 DOI |
18 | Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Investig 112:1776-1784. https://doi.org/10.1172/JCI20530 DOI |
19 | Bachman KE, Blair BG, Brenner K et al (2004) p21WAF1/CIP1 mediates the growth response to TGF-β in human epithelial cells. Cancer Biol Ther 3:221-225. https://doi.org/10.4161/cbt.3.2.666 DOI |
20 | Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890. https://doi.org/10.1016/j.cell.2009.11.007 DOI |
21 | Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69-84. https://doi.org/10.1038/s41580-018-0080-4 DOI |
22 | Kawami M, Harabayashi R, Miyamoto M, Harada R, Yumoto R, Takano M (2016) Methotrexate-induced epithelial-mesenchymal transition in the alveolar epithelial cell line A549. Lung 194:923-930. https://doi.org/10.1007/s00408-016-9935-7 DOI |
23 | Connolly EC, Freimuth J, Akhurst RJ (2012) Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 8:964-978. https://doi.org/10.7150/ijbs.4564 DOI |
24 | Chen KJ, Li Q, Wen CM, Duan ZX, Zhang JY, Xu C, Wang JM (2016) Bleomycin (BLM) induces epithelial-to-mesenchymal transition in cultured A549 cells via the TGF-β/Smad signaling pathway. J Cancer 7:1557-1564. https://doi.org/10.7150/jca.15566 DOI |
25 | Kubo K, Azuma A, Kanazawa M et al (2013) Japanese Respiratory Society Committee for formulation of consensus statement for the diagnosis and treatment of drug-induced lung injuries, consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51:260-277. https://doi.org/10.1016/j.resinv.2013.09.001 DOI |
26 | Yamamoto A, Kawami M, Konaka T, Takenaka S, Yumoto R, Takano M (2019) Anticancer drug-induced epithelial-mesenchymal transition via p53/miR-34a axis in A549/ABCA3 cells. J Pharm Pharm Sci 22:516-524. https://doi.org/10.18433/jpps30660 DOI |
27 | Sung JM, Cho HJ, Yi H et al (2008) Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 371:163-167. https://doi.org/10.1016/j.bbrc.2008.04.038 DOI |
28 | Morandi A, Taddei ML, Chiarugi P, Giannoni E (2017) Targeting the metabolic reprogramming that controls epithelial-to-mesenchymal transition in aggressive tumors. Front Oncol 7:40. https://doi.org/10.3389/fonc.2017.00040 DOI |
29 | Chen T, You Y, Jiang H, Wang ZZ (2017) Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol 232:3261-3272. https://doi.org/10.1002/jcp.25797 DOI |
30 | Salton F, Volpe MC, Confalonieri M (2019) Epithelial-mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis. Meddicina 55:83. https://doi.org/10.3390/medicina55040083 DOI |
31 | Takano M, Naka R, Sasaki Y, Nishimoto S, Yumoto R (2016) Effect of cigarette smoke extract on P-glycoprotein function in primary cultured and newly developed alveolar epithelial cells. Drug Metab Pharmacokinet 31:417-424. https://doi.org/10.1016/j.dmpk.2016.08.006 DOI |
32 | Wang Z, Jiang Y, Guan D et al (2013) Critical roles of p53 in epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma cells. PLoS ONE 8:e72846. https://doi.org/10.1371/journal.pone.0072846 DOI |
33 | Kolesnick R (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Investig 110:3-8. https://doi.org/10.1172/JCI16127 DOI |
34 | Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li J, Zhang Q (2017) Resveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res 36:19. https://doi.org/10.1186/s13046-016-0487-8 DOI |